Caricamento quotazioni...

Previsioni

Acquista
  4
Mantieni
  2
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Check-Cap conducts 1-for-7 reverse stock split

    Check-Cap will carry out a 1-for-7 reverse stock split on Wednesday, reducing outstanding common shares from about 9,463,062 to approximately 1,351,866. The common shares will remain listed on the Nasdaq Capital Market under the ticker MBAI and will be quoted adjusted for the split at the market open; the new CUSIP is M6S83C106. Fractional shares will be rounded up, and registered and brokerage-account shareholders do not need to take any action. The measure was approved by the board of directors and ratified by shareholders and is being undertaken in preparation for the planned merger with MBody AI, scheduled for Q3 2026 and still subject to Nasdaq approvals and customary closing conditions. » Altro su de.investing.com


  • Check-Cap submits audited financial statements of MBody AI and targets merger for H1 2026

    Check-Cap has filed financial reports with the SEC in connection with the planned merger with MBody AI and confirmed that preparations for the combination are continuing. The merger, already approved by Check-Cap shareholders on November 14, 2025, foresees MBody AI becoming a wholly owned subsidiary of Check-Cap. Check-Cap provided audited financial statements of MBody AI as of December 31, 2025, supplemented by unaudited pro forma financial information for the combined company. Closing is targeted for the first half of 2026 but is contingent on capital availability to meet NASDAQ requirements as well as regulatory and exchange reviews, with no guarantee of completion. » Altro su de.investing.com


  • Check-Cap meets NASDAQ minimum capital rule after adjustment to loan receivable

    Check-Cap says it now complies with NASDAQ listing rule 5550(b)(1) after restoring the collectible portion of a loan receivable from Apollo Technology Capital Corporation. According to unaudited financial statements for June 30, 2025, filed with the SEC on December 30, 2025, shareholders’ equity exceeds the required $2.5 million threshold. NASDAQ will continue to monitor compliance; delisting remains possible if Check-Cap fails to meet the rules in its next periodic report, though the company expects to be in compliance. » Altro su de.investing.com


  • Check-Cap shareholders approve merger with MBody AI and name change

    Shareholders of Check-Cap voted by a large majority to approve the merger with MBody AI under the agreement dated 12 September 2025, under which MBody AI will become a 100% subsidiary of Check-Cap. Also approved were a share consolidation at a ratio of 1:14 to 1:100 and the change of the company name to "MBody AI Ltd." effective on closing of the merger. The board of directors was confirmed; David Lontini remains in office as executive chairman with strong support. All resolutions reached the majorities required under Israeli law. » Altro su de.investing.com


  • Check-Cap grows through merger with MBody AI after strong share gains

    Check-Cap reports a definitive merger agreement with MBody AI, whose Orchestrator platform is said in the announcement to be used by global major customers. After the announcement the Check-Cap share rose sharply; the new company MBody AI Ltd. is to be 90% owned by MBody shareholders and 10% by Check-Cap shareholders. Check-Cap, with a current market capitalization of around USD 9.71 million, points to regulatory risks: the NASDAQ requires a plan to regain the minimum equity requirement by 20 October 2025, and an earnings report is due on 24 November. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo anno, Check-Cap ha registrato ricavi pari a 0 € e un utile netto di -24,17 Mln €
(EUR) 2024
YoY
Ricavi 0 -
Utile lordo -154,72K 19,32%
Utile netto -24,17 Mln 52,08%
EBITDA -8,94 Mln 44,01%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
9,87 Mln €
Numero di azioni
5,85 Mln
Massimo/minimo a 52 settimane
2,84 € - 0,51 €
Dividendi No
Beta
0,46
Rapporto P/E
0,44
Rapporto PEG
0,00
Rapporto P/B
0,53
Rapporto P/S
0,00

Profilo aziendale

Check-Cap Ltd., una società di diagnostica medica in fase clinica, si occupa dello sviluppo di una tecnologia di screening basata su capsule che utilizza raggi X a dosi ultra-basse per esaminare il rivestimento interno del colon alla ricerca di polipi precancerosi e di altre anomalie strutturali, in Israele. Il suo sistema C-Scan è composto da C-Scan Cap, una capsula per la scansione a raggi X per il rilevamento di presunti polipi; C-Scan Track, un sistema monouso applicato sulla schiena del paziente tramite cerotti cutanei biocompatibili; e C-Scan View, un'applicazione software client/server che consente il download dei dati della procedura dal C-Scan Track, l'analisi dei dati e la generazione di report. La società è stata costituita nel 2004 ed è con sede a Isfiya, in Israele.

Nome
Check-Cap
CEO
David Lontini
Sede centrale Isfiya,
Israele
Sito web
Settore
Sanità
Industria
Attrezzature e forniture sanitarie
Quotazione in borsa
04/03/2015
Dipendenti 85

Simboli di borsa

Borsa Simbolo
NASDAQ
CHEK
Frankfurt
7CC.F
München
7CC.MU
🍪

Parqet  usa i cookie. Scopri di più